South Korea
· Delayed Price · Currency is KRW ST Pharm Statistics
Total Valuation
ST Pharm has a market cap or net worth of KRW 2.44 trillion. The enterprise value is 2.40 trillion.
| Market Cap | 2.44T |
| Enterprise Value | 2.40T |
Important Dates
The next estimated earnings date is Thursday, February 5, 2026.
| Earnings Date | Feb 5, 2026 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
ST Pharm has 20.70 million shares outstanding. The number of shares has increased by 7.23% in one year.
| Current Share Class | 20.70M |
| Shares Outstanding | 20.70M |
| Shares Change (YoY) | +7.23% |
| Shares Change (QoQ) | -2.51% |
| Owned by Insiders (%) | 7.39% |
| Owned by Institutions (%) | 6.57% |
| Float | 12.98M |
Valuation Ratios
The trailing PE ratio is 65.73 and the forward PE ratio is 39.97.
| PE Ratio | 65.73 |
| Forward PE | 39.97 |
| PS Ratio | 7.67 |
| PB Ratio | 4.39 |
| P/TBV Ratio | 4.52 |
| P/FCF Ratio | 162.82 |
| P/OCF Ratio | 26.88 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 30.31, with an EV/FCF ratio of 160.15.
| EV / Earnings | 65.13 |
| EV / Sales | 7.55 |
| EV / EBITDA | 30.31 |
| EV / EBIT | 46.93 |
| EV / FCF | 160.15 |
Financial Position
The company has a current ratio of 2.04, with a Debt / Equity ratio of 0.14.
| Current Ratio | 2.04 |
| Quick Ratio | 0.96 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 1.01 |
| Debt / FCF | 5.33 |
| Interest Coverage | 6.65 |
Financial Efficiency
Return on equity (ROE) is 6.89% and return on invested capital (ROIC) is 5.16%.
| Return on Equity (ROE) | 6.89% |
| Return on Assets (ROA) | 4.44% |
| Return on Invested Capital (ROIC) | 5.16% |
| Return on Capital Employed (ROCE) | 8.86% |
| Revenue Per Employee | 485.98M |
| Profits Per Employee | 56.33M |
| Employee Count | 655 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 1.16 |
Taxes
In the past 12 months, ST Pharm has paid 12.92 billion in taxes.
| Income Tax | 12.92B |
| Effective Tax Rate | 26.42% |
Stock Price Statistics
The stock price has increased by +35.48% in the last 52 weeks. The beta is 0.25, so ST Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +35.48% |
| 50-Day Moving Average | 99,276.00 |
| 200-Day Moving Average | 86,618.50 |
| Relative Strength Index (RSI) | 70.36 |
| Average Volume (20 Days) | 188,648 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ST Pharm had revenue of KRW 318.32 billion and earned 36.89 billion in profits. Earnings per share was 1,795.21.
| Revenue | 318.32B |
| Gross Profit | 124.70B |
| Operating Income | 51.45B |
| Pretax Income | 48.90B |
| Net Income | 36.89B |
| EBITDA | 79.51B |
| EBIT | 51.45B |
| Earnings Per Share (EPS) | 1,795.21 |
Balance Sheet
The company has 119.38 billion in cash and 80.00 billion in debt, giving a net cash position of 39.38 billion or 1,902.17 per share.
| Cash & Cash Equivalents | 119.38B |
| Total Debt | 80.00B |
| Net Cash | 39.38B |
| Net Cash Per Share | 1,902.17 |
| Equity (Book Value) | 555.98B |
| Book Value Per Share | 26,893.56 |
| Working Capital | 181.76B |
Cash Flow
In the last 12 months, operating cash flow was 90.88 billion and capital expenditures -75.88 billion, giving a free cash flow of 15.00 billion.
| Operating Cash Flow | 90.88B |
| Capital Expenditures | -75.88B |
| Free Cash Flow | 15.00B |
| FCF Per Share | 724.73 |
Margins
Gross margin is 39.17%, with operating and profit margins of 16.16% and 11.59%.
| Gross Margin | 39.17% |
| Operating Margin | 16.16% |
| Pretax Margin | 15.36% |
| Profit Margin | 11.59% |
| EBITDA Margin | 24.98% |
| EBIT Margin | 16.16% |
| FCF Margin | 4.71% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.42%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 0.42% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.31% |
| Buyback Yield | -7.23% |
| Shareholder Yield | -6.80% |
| Earnings Yield | 1.51% |
| FCF Yield | 0.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ST Pharm has an Altman Z-Score of 6.47 and a Piotroski F-Score of 6.
| Altman Z-Score | 6.47 |
| Piotroski F-Score | 6 |